Long-term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetes (vol 61, pg 1614, 2007)

被引：0
|
作者：
Barnett, A. H.
Lange, P.
Dreyer, M.
Serdarevic-Pehar, M.
机构：
来源：
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2008年 / 62卷 / 01期
关键词：
D O I：
10.1111/j.1742-1241.2007.01664.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [1] Long-term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetes
    Barnett, A. H.
    Lange, P.
    Dreyer, M.
    Serdarevic-Pehar, M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (10) : 1614 - 1625
  • [2] Sustained efficacy and tolerability of inhaled human insulin (Exubera®).: Therapy over 2 years:: patients with type 2 diabetes
    Cefalu, W.
    Rosenstock, J.
    Klioze, S.
    Foyt, H.
    Ogawa, M.
    St Aubin, L.
    Duggan, W.
    DIABETOLOGIA, 2006, 49 : 615 - 615
  • [3] Sustained efficacy and tolerability of inhaled human insulin (Exubera®).: Therapy over 2 years:: patients with type 1 diabetes
    Skyler, J.
    Jovanovic, L.
    Klioze, S.
    Reis, J.
    Duggan, W.
    DIABETOLOGIA, 2006, 49 : 118 - 118
  • [4] Balancing compliance, patient satisfaction and improved glycaemic control in patients with type 1 and type 2 diabetes:: long-term studies with inhaled insulin (Exubera®)
    Gerber, RA
    Cappelleri, JC
    Nadkarni, S
    Petrie, CD
    Rosenstock, J
    DIABETOLOGIA, 2002, 45 : A240 - A241
  • [5] Long-Term Effectiveness of Dapagliflozin Over 104 Weeks in Patients With Type 2 Diabetes Poorly Controlled With Insulin
    Wilding, John P.
    Woo, Vincent C.
    Rohwedder, Katja
    Sugg, Jennifer E.
    Parikh, Shamik J.
    DIABETES, 2012, 61 : A267 - A268
  • [6] Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin
    Rohwedder, K.
    Wilding, J. P. H.
    Woo, V.
    Sugg, J.
    Parikh, S.
    DIABETOLOGIA, 2012, 55 : S309 - S309
  • [7] Titration of Inhaled Human Insulin (Exubera) in a Treat-to-Target Regimen for Patients with Type 2 Diabetes
    Hollander, Priscilla A.
    Cefalu, William T.
    Mitnick, Michael
    Lawrence, David
    Rosenstock, Julio
    DIABETES TECHNOLOGY & THERAPEUTICS, 2010, 12 (03) : 185 - 191
  • [8] Exubera Inhaled Insulin in Patients with Type 1 and Type 2 Diabetes: The First 12 Months
    Alabraba, Victoria
    Farnsworth, Adele
    Leigh, Rebecca
    Dodson, Paul
    Gough, Stephen C. L.
    Smyth, Theresa
    DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 (07) : 427 - 430
  • [9] Inhaled Insulin (Exubera®) Achieves Better A1c-Levels Than Insulin Glargine in Patients with Type 2 Diabetes mellitus Poorly Controlled by Oral Antidiabetic Agents
    Heise, Tim
    Mathieu, Chantal
    Hey-Hadavi, Judith
    Strack, Thomas
    Lawrence, David E.
    DIABETES, 2009, 58 : A528 - A528
  • [10] Inhaled insulin (Exubera®) leads to a greater potential acceptance of insulin therapy in patients with uncontrolled type 2 diabetes
    Freemantle, N
    Blonde, L
    Bolinder, B
    Hompesch, M
    Duhot, D
    Eggertsen, R
    Hobbs, FDR
    Martinez, L
    Ross, S
    Stridde, E
    DIABETES, 2004, 53 : A466 - A466
12345